We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for ivosidenib (Servier Laboratories Australia Pty Ltd)
Active ingredients
ivosidenib
Date of review outcome
Lapse date
Type
Priority review
Indication
TIBSOVO monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 (IDH1) mutation, who were previously treated by at least one prior line of systemic therapy
Therapeutic area
Oncology